Therefore, the HSP70-HER-2-PCs were an improved individual tumor vaccine that had a more effective antigenicity to SKBR-3 cells than other types of HSP70-PCs, and induced more tumor-specific CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.